Graduate School of Hebei Medical University, Shijiazhuang, Hebei, China.
Hepatobiliary Surgery Department of the Fourth Hospital of Hebei Medical University, 169 Tianshan Street, Shijiazhuang, Hebei, China.
BMC Gastroenterol. 2024 Mar 4;24(1):93. doi: 10.1186/s12876-024-03185-z.
Hepatocellular carcinoma (HCC) has a poor prognosis, and alpha-fetoprotein (AFP) is widely used to evaluate HCC. However, the proportion of AFP-negative individuals cannot be disregarded. This study aimed to establish a nomogram of risk factors affecting the prognosis of patients with AFP-negative HCC and to evaluate its diagnostic efficiency.
Data from patients with AFP-negative initial diagnosis of HCC (ANHC) between 2004 and 2015 were collected from the Surveillance, Epidemiology, and End Results database for model establishment and validation. We randomly divided overall cohort into the training or validation cohort (7:3). Univariate and multivariate Cox regression analysis were used to identify the risk factors. We constructed nomograms with overall survival (OS) and cancer-specific survival (CSS) as clinical endpoint events and constructed survival analysis by using Kaplan-Meier curve. Also, we conducted internal validation with Receiver Operating Characteristic (ROC) analysis and Decision curve analysis (DCA) to validate the clinical value of the model.
This study included 1811 patients (1409 men; 64.7% were Caucasian; the average age was 64 years; 60.7% were married). In the multivariate analysis, the independent risk factors affecting prognosis were age, ethnicity, year of diagnosis, tumor size, tumor grade, surgery, chemotherapy, and radiotherapy. The nomogram-based model related C-indexes were 0.762 (95% confidence interval (CI): 0.752-0.772) and 0.752 (95% CI: 0.740-0.769) for predicting OS, and 0.785 (95% CI: 0.774-0.795) and 0.779 (95% CI: 0.762-0.795) for predicting CSS. The nomogram model showed that the predicted death was consistent with the actual value. The ROC analysis and DCA showed that the nomogram had good clinical value compared with TNM staging.
The age(HR:1.012, 95% CI: 1.006-1.018, P-value < 0.001), ethnicity(African-American: HR:0.946, 95% CI: 0.783-1.212, P-value: 0.66; Others: HR:0.737, 95% CI: 0.613-0.887, P-value: 0.001), tumor diameter(HR:1.006, 95% CI: 1.004-1.008, P-value < 0.001), year of diagnosis (HR:0.852, 95% CI: 0.729-0.997, P-value: 0.046), tumor grade(Grade 2: HR:1.124, 95% CI: 0.953-1.326, P-value: 0.164; Grade 3: HR:1.984, 95% CI: 1.574-2.501, P-value < 0.001; Grade 4: HR:2.119, 95% CI: 1.115-4.027, P-value: 0.022), surgery(Liver Resection: HR:0.193, 95% CI: 0.160-0.234, P-value < 0.001; Liver Transplant: HR:0.102, 95% CI: 0.072-0.145, P-value < 0.001), chemotherapy(HR:0.561, 95% CI: 0.471-0.668, P-value < 0.001), and radiotherapy(HR:0.641, 95% CI: 0.463-0.887, P-value:0.007) were independent prognostic factors for patients with ANHC. We developed a nomogram model for predicting the OS and CSS of patients with ANHC, with a good predictive performance.
肝细胞癌(HCC)预后较差,甲胎蛋白(AFP)广泛用于评估 HCC。然而,不能忽视 AFP 阴性个体的比例。本研究旨在建立 AFP 阴性 HCC 患者预后影响因素的列线图,并评估其诊断效率。
从 2004 年至 2015 年期间 Surveillance, Epidemiology, and End Results 数据库中收集 AFP 阴性初诊 HCC(ANHC)患者的数据,用于模型建立和验证。我们将整体队列随机分为训练或验证队列(7:3)。采用单因素和多因素 Cox 回归分析确定风险因素。我们以总生存(OS)和癌症特异性生存(CSS)为临床终点事件构建列线图,并通过 Kaplan-Meier 曲线进行生存分析。我们还通过接受者操作特征(ROC)分析和决策曲线分析(DCA)进行内部验证,以验证模型的临床价值。
本研究纳入了 1811 例患者(1409 例男性;64.7%为白种人;平均年龄为 64 岁;60.7%已婚)。多因素分析显示,影响预后的独立危险因素为年龄、种族、诊断年份、肿瘤大小、肿瘤分级、手术、化疗和放疗。基于列线图的模型相关 C 指数分别为 0.762(95%置信区间(CI):0.752-0.772)和 0.752(95% CI:0.740-0.769),用于预测 OS,0.785(95% CI:0.774-0.795)和 0.779(95% CI:0.762-0.795)用于预测 CSS。列线图模型表明,预测死亡率与实际死亡率一致。ROC 分析和 DCA 表明,与 TNM 分期相比,列线图具有较好的临床价值。
年龄(HR:1.012,95%CI:1.006-1.018,P 值<0.001)、种族(非裔美国人:HR:0.946,95%CI:0.783-1.212,P 值:0.66;其他:HR:0.737,95%CI:0.613-0.887,P 值:0.001)、肿瘤直径(HR:1.006,95%CI:1.004-1.008,P 值<0.001)、诊断年份(HR:0.852,95%CI:0.729-0.997,P 值:0.046)、肿瘤分级(Grade 2:HR:1.124,95%CI:0.953-1.326,P 值:0.164;Grade 3:HR:1.984,95%CI:1.574-2.501,P 值<0.001;Grade 4:HR:2.119,95%CI:1.115-4.027,P 值:0.022)、手术(肝切除术:HR:0.193,95%CI:0.160-0.234,P 值<0.001;肝移植术:HR:0.102,95%CI:0.072-0.145,P 值<0.001)、化疗(HR:0.561,95%CI:0.471-0.668,P 值<0.001)和放疗(HR:0.641,95%CI:0.463-0.887,P 值:0.007)是影响 ANHC 患者预后的独立预测因素。我们开发了一种预测 ANHC 患者 OS 和 CSS 的列线图模型,具有良好的预测性能。